Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease
- PMID: 28865675
- PMCID: PMC5750096
- DOI: 10.1016/j.kint.2017.06.028
Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease
Abstract
Galectin-3 has been proposed as a novel biomarker of heart failure and cardiac fibrosis, and may also be associated with fibrosis of other organs such as the kidney. To determine this, we prospectively analyzed data from 9,148 Atherosclerosis Risk in Communities (ARIC) Study participants with measured plasma galectin-3 levels (baseline, visit 4, 1996-98) and without prevalent chronic kidney disease (CKD) or heart failure. We identified 1,983 incident CKD cases through December 31, 2013 over a median follow-up of 16 years. At baseline, galectin-3 was cross-sectionally associated with estimated glomerular filtration rate and urine albumin-to-creatinine ratio; both significant. The results were adjusted for age, sex, race-center, education, physical activity, smoking status, body mass index, systolic blood pressure, anti-hypertensive medication use, history of cardiovascular disease, diabetes, fasting blood glucose, and rs4644 (a single nucleotide polymorphism of galactin-3). There was a significant, graded, and positive association between galectin-3 and incident CKD (quartile 4 vs. 1 hazard ratio: 2.22 [95% confidence interval: 1.89, 2.60]). The association was attenuated but remained significant after adjustment for estimated glomerular filtration rate, urine albumin-to-creatinine ratio, troponin T, and N-terminal pro-brain natriuretic peptide (quartile 4 vs. 1 hazard ratio: 1.75 [95% confidence interval: 1.49, 2.06]), and was stronger among those with hypertension at baseline (significant interaction). Thus, in this community-based population, higher plasma galectin-3 levels were associated with an elevated risk of developing incident CKD, particularly among those with hypertension.
Keywords: chronic kidney disease; fibrosis; galectin-3; hypertension.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Comment in
-
Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney disease.Kidney Int. 2018 Jan;93(1):270. doi: 10.1016/j.kint.2017.10.009. Kidney Int. 2018. PMID: 29291821 No abstract available.
References
-
- Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17. - PubMed
-
- Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994;269:20807–20810. - PubMed
-
- de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811–817. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHSN268201100012C/HL/NHLBI NIH HHS/United States
- HHSN268201100009I/HL/NHLBI NIH HHS/United States
- HHSN268201100010C/HL/NHLBI NIH HHS/United States
- HHSN268201100008C/HL/NHLBI NIH HHS/United States
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- HHSN268201100008I/HL/NHLBI NIH HHS/United States
- R01 DK089174/DK/NIDDK NIH HHS/United States
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- K01 DK107782/DK/NIDDK NIH HHS/United States
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- K24 DK106414/DK/NIDDK NIH HHS/United States
- U01 DK085689/DK/NIDDK NIH HHS/United States
- HHSN268201100009C/HL/NHLBI NIH HHS/United States
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
- R01 HL134320/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
